To date there is limited data on the immune profile and outcomes of solid organ transplant recipients who encounter COVID-19 infection early post-transplant. Here we present a unique case where the kidney recipient’s transplant surgery coincided with a positive SARS-CoV-2 test and the patient subsequently developed symptomatic COVID-19 perioperatively. We performed comprehensive immunological monitoring of cellular, proteomic, and serological changes during the first 4 critical months post-infection. We showed that continuation of basiliximab induction and maintenance of triple immunosuppression did not significantly impair the host’s ability to mount a robust immune response against symptomatic COVID-19 infection diagnosed within the first week post-transplant.
【저자키워드】 COVID-19, immune response, immunosuppressants, Transplant, induction therapy, 【초록키워드】 Immune profile, Immunosuppression, outcome, kidney, COVID-19 infection, Transplant, symptomatic, serological, change, Critical, proteomic, solid organ transplant, cellular, symptomatic COVID-19, solid organ, maintenance, Post-infection, positive, recipient, SARS-CoV-2 test, basiliximab, immunological, robust, performed, significantly, the patient, diagnosed, unique, impair, 【제목키워드】 SARS-CoV-2, Profiling, report, recipient, Comprehensive,